173 related articles for article (PubMed ID: 36006771)
61. [Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].
Luo DL; Liu YH; Zhuang HG; Li L; Xu FP; Zhang F; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):235-9. PubMed ID: 21615996
[TBL] [Abstract][Full Text] [Related]
62.
Vermaat JS; Somers SF; de Wreede LC; Kraan W; de Groen RAL; Schrader AMR; Kerver ED; Scheepstra CG; Berenschot H; Deenik W; Wegman J; Broers R; de Boer JD; Nijland M; van Wezel T; Veelken H; Spaargaren M; Cleven AH; Kersten MJ; Pals ST
Haematologica; 2020; 105(2):424-434. PubMed ID: 31123031
[TBL] [Abstract][Full Text] [Related]
63. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.
Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S
Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251
[TBL] [Abstract][Full Text] [Related]
64. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.
Kim S; Nam SJ; Kwon D; Kim H; Lee E; Kim TM; Heo DS; Park SH; Kim CW; Jeon YK
BMC Cancer; 2016 Jun; 16():363. PubMed ID: 27286976
[TBL] [Abstract][Full Text] [Related]
65. CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases.
Li Y; Hu S; Zuo Z; Hong M; Lin P; Li S; Konoplev S; Wang Z; Khoury JD; Young KH; Medeiros LJ; Yin CC
Mod Pathol; 2015 Jun; 28(6):787-98. PubMed ID: 25743023
[TBL] [Abstract][Full Text] [Related]
66. De novo nodal diffuse large B-cell lymphoma: identification of biologic prognostic factors.
Abd El-Hameed A
J Egypt Natl Canc Inst; 2005 Mar; 17(1):20-8. PubMed ID: 16353079
[TBL] [Abstract][Full Text] [Related]
67. [Aggressive B-cell lymphomas of gastrointestinal tract: a clinicopathologic analysis of 54 cases].
Zhou J; Xia C; Shen Q; Yin H; Zhang X; Shi Q; Zhou X; Ma J
Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):8-14. PubMed ID: 24713242
[TBL] [Abstract][Full Text] [Related]
68. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
[TBL] [Abstract][Full Text] [Related]
69. [CD5 expression is an adverse prognostic factor in diffuse large B-cell lymphoma].
Zheng Y; Ma XB; Jiang J; Wang YP
Zhonghua Bing Li Xue Za Zhi; 2012 Mar; 41(3):156-60. PubMed ID: 22800477
[TBL] [Abstract][Full Text] [Related]
70. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
Hyo R; Tomita N; Takeuchi K; Aoshima T; Fujita A; Kuwabara H; Hashimoto C; Takemura S; Taguchi J; Sakai R; Fujita H; Fujisawa S; Ogawa K; Motomura S; Suzuki R; Ishigatsubo Y
Hematol Oncol; 2010 Mar; 28(1):27-32. PubMed ID: 19358143
[TBL] [Abstract][Full Text] [Related]
71. Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.
Xu-Monette ZY; Wei L; Fang X; Au Q; Nunns H; Nagy M; Tzankov A; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Sun X; Han X; Go H; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Albitar M; You H; Young KH
Clin Cancer Res; 2022 Mar; 28(5):972-983. PubMed ID: 34980601
[TBL] [Abstract][Full Text] [Related]
72. Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature.
Suguro M; Tagawa H; Kagami Y; Okamoto M; Ohshima K; Shiku H; Morishima Y; Nakamura S; Seto M
Cancer Sci; 2006 Sep; 97(9):868-74. PubMed ID: 16856881
[TBL] [Abstract][Full Text] [Related]
73. Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL.
Li L; Zhang X; Zhang T; Song Z; Hu G; Li W; Li L; Qiu L; Qian Z; Zhou S; Liu X; Feng L; Pan Y; Zhai Q; Meng B; Ren X; Fu K; Wang P; Wang X; Zhang H
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):e381-e389. PubMed ID: 29983382
[TBL] [Abstract][Full Text] [Related]
74. [MYC and BCL-2 protein co-expression and prognosis of patients with diffuse large B-cell lymphoma: a propensity score matching analysis].
Zhan J; Yang SJ; Zhang W; Zhou DB; Zhang Y; Wang W; Wei C
Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):41-47. PubMed ID: 35231992
[No Abstract] [Full Text] [Related]
75. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
[TBL] [Abstract][Full Text] [Related]
76. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
[TBL] [Abstract][Full Text] [Related]
77. Expressions of SH3BP5, LMO3, and SNAP25 in diffuse large B-cell lymphoma cells and their association with clinical features.
Kobayashi K; Yamaguchi M; Miyazaki K; Imai H; Yokoe K; Ono R; Nosaka T; Katayama N
Cancer Med; 2016 Aug; 5(8):1802-9. PubMed ID: 27184832
[TBL] [Abstract][Full Text] [Related]
78. Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma.
Zhang W; Yang L; Guan YQ; Shen KF; Zhang ML; Cai HD; Wang JC; Wang Y; Huang L; Cao Y; Wang N; Tan XH; Young KH; Xiao M; Zhou JF
BMC Cancer; 2020 Jul; 20(1):714. PubMed ID: 32736575
[TBL] [Abstract][Full Text] [Related]
79. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
[TBL] [Abstract][Full Text] [Related]
80. CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma.
Gong QX; Wang Z; Liu C; Li X; Lu TX; Liang JH; Xu W; Li JY; Zhang ZH
J Clin Pathol; 2018 Sep; 71(9):795-801. PubMed ID: 29666157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
